Next 10 |
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a pha...
Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Ma...
2024-04-16 16:24:42 ET Summary The healthcare sector is overvalued by 14% based on 11-year averages. Healthcare providers are not far from their valuation baseline, while the most overvalued subsector is healthcare equipment. Fast facts on Fidelity MSCI Health Care Index ETF, ...
2024-04-10 09:00:04 ET Akash Tewari from Jefferies issued a price target of $50.00 for ALKS on 2024-04-10 07:44:00. The adjusted price target was set to $50.00. At the time of the announcement, ALKS was trading at $26.73. The overall price target consensus is at $31.33 w...
2024-04-09 16:29:10 ET Summary Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 study for ALKS-2680 in Narcolepsy Type 2 later this y...
2024-04-09 15:15:03 ET UBS analyst issues BUY recommendation for ALKS on April 9, 2024 01:01PM ET. The previous analyst recommendation was Buy. ALKS was trading at $26.765 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst r...
2024-04-09 13:30:01 ET Jefferies analyst issues BUY recommendation for ALKS on April 9, 2024 12:04PM ET. The previous analyst recommendation was Buy. ALKS was trading at $27 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst...
2024-04-09 13:00:03 ET Akash Tewari from Jefferies issued a price target of $25.00 for ALKS on 2024-04-09 12:04:00. The adjusted price target was set to $25.00. At the time of the announcement, ALKS was trading at $26.95. The overall price target consensus is at $32.00 w...
2024-04-09 09:49:40 ET Summary Alkermes' spinoff transaction with Mural Oncology resulted in cost cutting and higher EBITDA margins, with strong 2023 profitability gains expected to continue into 2024. The stock is currently undervalued compared to peers, but capital allocation in...
2024-04-09 08:59:00 ET U.S. stock index futures on Tuesday pointed to a slightly higher open, a day ahead of a key consumer inflation report. Here are some stocks to watch on Tuesday: ... Read the full article on Seeking Alpha For further details see: 4 stocks to wa...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc Company Name:
ALKS Stock Symbol:
NASDAQ Market:
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a pha...
Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Ma...
2024-04-10 09:00:04 ET Akash Tewari from Jefferies issued a price target of $50.00 for ALKS on 2024-04-10 07:44:00. The adjusted price target was set to $50.00. At the time of the announcement, ALKS was trading at $26.73. The overall price target consensus is at $31.33 w...